Core Insights - The company is closely monitoring market dynamics and is implementing innovative marketing strategies to enhance public awareness of related diseases and stimulate demand for vaccinations [1][2] - The approval of the nasal spray influenza live attenuated vaccine marks a significant addition to the company's product lineup, enhancing its core competitiveness [1] - The company is actively conducting clinical research to expand the target population for its influenza vaccine, aiming to include a broader age range [1] Research and Development - The company has 16 ongoing research projects, with 11 in clinical trial approval or registration stages, and has invested 98.2 million yuan, accounting for 34.47% of its revenue [2] - Several products in the pipeline have made significant progress, including the recombinant shingles vaccine and adjuvanted influenza vaccines, with some already receiving clinical trial approvals [2] - The company is exploring new marketing models in line with product characteristics and public health policies [2] Marketing and Public Engagement - The company is enhancing awareness of the shingles vaccine through academic promotion and public education, aiming to correct misconceptions and increase vaccination rates [3] - Collaborations with local governments are being pursued to integrate vaccines into public health projects, reducing the economic and psychological burdens of shingles on patients [3] - The company is expanding its overseas market presence through international industry exhibitions and is progressing with product registrations in countries like Russia [3]